How big is the chronic pruritus therapeutics market today, and what are its future growth expectations?
The chronic pruritus therapeutics market size has grown strongly in recent years. It will grow from $10.17 billion in 2024 to $10.94 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising prevalence of chronic pruritus, rising demand for effective treatments, growing regulatory approvals, rise in product approvals, increase in industry participants’ mergers, collaborations, and acquisitions.
The chronic pruritus therapeutics market size is expected to see strong growth in the next few years. It will grow to $14.49 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to rising awareness, rise in atopic dermatitis, increasing focus on personalized medicine, increasing prevalence of dermatological conditions, growing patient population. Major trends in the forecast period include introducing innovative medicines, development of novel biologics and targeted therapies, technological advancements, integration of advanced drug delivery systems, collaborations between pharmaceutical companies and research institutions, digital health technologies including telemedicine.
Get Your Free Sample of The Global Chronic Pruritus Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp
What have been the primary factors driving the chronic pruritus therapeutics market’s growth?
The rising prevalence of atopic dermatitis is expected to propel the growth of the chronic pruritus therapeutics market going forward. Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by redness, itching, dryness, and irritation, commonly affecting individuals with a family history of allergies, asthma, or hay fever. The rising prevalence of atopic dermatitis can be attributed to factors such as genetic predisposition, environmental changes, lifestyle factors, the hygiene hypothesis, increased allergen exposure, and skin microbiome imbalances. Chronic pruritus therapeutics alleviates the persistent itching associated with atopic dermatitis by targeting underlying inflammatory pathways, reducing skin irritation, and improving patient comfort. For instance, in 2022, according to the International Eczema Council, a US-based nonprofit organization, approximately 223 million people globally were living with atopic dermatitis (GBD 2022), including 43 million children aged 1-4, highlighting the condition’s significant prevalence in early childhood. Therefore, the rising prevalence of atopic dermatitis is driving the growth of the chronic pruritus therapeutics market.
What are the key segments within the chronic pruritus therapeutics market?
The chronic pruritus therapeutics market covered in this report is segmented –
1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types
2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types
3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers
Subsegments:
1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics
4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants
5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy
7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report
Which key players are shaping the chronic pruritus therapeutics market?
Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.
How will emerging trends drive the chronic pruritus therapeutics market throughout the forecast period?
Major companies operating in the chronic pruritus therapeutics market are focusing on development of innovative formulations such as intravenous (IV) injection to enhance treatment efficacy and provide faster relief for patients. Intravenous (IV) injection helps treat pruritus by delivering medications, such as antihistamines or corticosteroids, directly into the bloodstream to quickly alleviate itching and reduce inflammation. For instance, in September 2023, Cara Therapeutics Inc., a US-based company that manufactures therapeutics announced that its partner company Maruishi Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company received the approval for Korsuva IV injection syringe, a treatment for pruritus in hemodialysis patients by the Japan’s Ministry of Health, Labour and Welfare, a Japan-based government agency. This approval was based on positive Phase 3 clinical trial results conducted by Maruishi in collaboration with Kissei Pharmaceutical Co., Ltd. The treatment showed significant improvements in itching scores compared to a placebo, and it was well-tolerated by patients. The approval also triggers a $1.5 million milestone payment to Cara Therapeutics, the developer of Korsuva, as per the terms of their licensing agreement with Maruishi.
How do regional factors impact the chronic pruritus therapeutics market, and which region is the largest contributor?
North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Chronic Pruritus Therapeutics Market Report 2025 Offer?
The chronic pruritus therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Chronic pruritus therapy refers to treatments aimed at managing or alleviating persistent itching (pruritus) that lasts for six weeks or more. Chronic pruritus is managed with a combination of therapies that are tailored to the specific underlying cause, and treatment can be adjusted based on how the patient responds.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
